Dr. David Seal has extensive experience conducting social-behavioral formative and intervention research within a multicultural, community-based, participatory framework. He has been the Principal Investigator on HIV-prevention intervention studies with men who have sex with men, prison populations, rural opioid users, and delinquent female adolescents. He has also conducted funded studies to explore sexual behavior among at-risk heterosexuals in Syria; the impact of intersecting identities on risk behavior among racial and ethnic minority men; the impact of displacement among Syrian MSM in Lebanon; and emotional and sexual intimacy among gay, lesbian, and heterosexual couples. Dr. Seal has also been involved in youth violence prevention initiatives.
UG3-DA044826 Seal & Westergaard (Co-PIs) 8/15/17-7/21/19
NIH / NIDA Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic Grant Amount: $584,925
This project aims to (1)estimate the prevalence of HIV, viral hepatitis, and sexually transmitted infections among people who inject opioids, and the availability of essential prevention services, in 6 rural Wisconsin counties; (2) comprehensively assess unmet needs and available resources for the provision of essential prevention services for people who inject opioids in rural communities; and (3) evaluate the impact of the Client-Centered Prevention Home model, deployed within syringe service programs in counties with high burden of opioid injection, on the proportion of clients who receive the package of 9 essential services endorsed by the World Health Organization to prevent HIV/HCV in people who inject drugs.
R21HD089820 Heimer (PI) 3/31/17-6/30/19
NIH / NIMH Addressing Disparities in HIV Testing and Care among Displaced MSM Grant Amount: $226,547
The goal of this exploratory study is to obtain a larger sample of 1,000 MSM consisting approximately of 60% Syrian-born and 40% Lebanese-born MSM in order to (1) confirm the increased HIV prevalence in the MSM population, (2) quantify differences in HIV testing rates and HIV incidence, and (3) determine differences in access to and retention in HIV treatment for those testing HIV positive. Co-Investigator